AXGN · Axogen, Inc.
$41.14
+1.65 (+4.18%)
At close · Jul 27
Market Cap
$2.19B
Shares
53.18M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$41.14
Open$39.77
Day$39.61–41.27
52W$12.39–46.95
Avg vol 30d1.3M
Short int5.4M · 10.2% float · 3.6d
Short vol60%
Last earningsJul 29, 2026
DataJan 2020–Jul 2026
Filing10-Q · Apr 28
Up next
Next earnings call
Jul 29, 2026
Scheduled
· this week
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 28, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+23%
above
Price vs 50-day avg
−2%
below
RSI (14)
49
neutral
MACD trend
Negative
52-week position
83%
mid-range
Momentum
relative strength
1-month return
−8%
trailing
6-month return
+17%
trailing
YTD return
+26%
this year
Relative strength
+11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $42 › 200d $34 — 50d above 200d
Institutional flow
Distributing
36 of 220 funds reported for Jun 30 · net -63.0K sh shares · +8 new
Insider flow
Distributing
Net -$1.7M over 90 days · 100% sells
Short interest
Rising
10.24% of float · ▲ +17.4% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
220 holders — near 3-yr high, broad support
Squeeze score
80
high risk · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
Gross margin
74%
contracting
EPS growth
−48%
Y/Y
Free cash flow
$-2.9M
Balance sheet
$14.6M
net debt
Quant / Vol
risk profile
Volatility
54%
annualized · 1-yr
Max drawdown
−19%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Apr 28, 2026
Revenue growth
· full-year 2026
Initiated
at least $270M
prior FY $225.21M
midpoint +19.9% Y/Y
Gross margin
· full-year 2026
Initiated
74% – 76%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+23%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
49
Neutral
MACD trend
Negative
Bearish
52-week position
83%
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $42 › 200d $34 — 50d above 200d
Institutional flow
Distributing
36 of 220 funds reported for Jun 30 · net -63.0K sh shares · +8 new
Insider flow
Distributing
Net -$1.7M over 90 days · 100% sells
Short interest
Rising
10.24% of float · ▲ +17.4% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
220 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $12
Now $41 · 83%
52-wk high $47
vs 200-day avg +23%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $5.7M | first quarter 2026 | — |
|
|
|||
| Adjusted net income non-GAAP | $4.1M | first quarter 2026 | — |
| Newly covered lives | 19.8M | full-year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AXGN
this stock
Axogen, Inc.
|
$2.19B | +25.7% | +20.2% | — | 10.2% |
|
ABT
Abbott Laboratories
|
$182.00B | -16.2% | +5.7% | 29.3 | 1.4% |
|
SYK
Stryker Corp
|
$129.09B | -3.9% | +11.2% | 39.0 | 1.8% |
|
MDT
Medtronic plc
|
$107.81B | -11.6% | +8.4% | 22.6 | 1.5% |
|
BSX
Boston Scientific Corp
|
$67.64B | -52.3% | +5.5% | 19.0 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AXGN | +4.2% | -8.4% | +17.5% | -10.9% | +25.7% |
| SPY | -0.6% | +0.7% | +6.8% | -1.0% | +8.4% |
| vs SPY | +4.8% | -9.1% | +10.7% | -9.9% | +17.3% |
Key facts
CIK
805928
CUSIP
05463X106
13F (30d)
36 filings
36 filers
Visit website
Investor relations